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Abstract
Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leuke-
mia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against
BCR-ABL and activity against most imatinib-resistant BCR-ABL mutations, have each shown superior efficacy com-
pared with imatinib for first-line treatment of chronic-phase CML in randomized phase 3 trials. With 14 months
follow-up time, available data suggest no obvious differences in efficacy between dasatinib and nilotinib.
Compared with imatinib, dasatinib is associated with higher rates of pleural effusion and thrombocytopenia, but
lower rates of edema, gastrointestinal AEs, musculoskeletal AEs, and rash. Nilotinib is associated with higher rates of
dermatologic toxicity, headache, and biochemical abnormalities associated with hepatic and pancreatic toxicity
compared with imatinib, but lower rates of edema, gastrointestinal AEs, muscle spasm, and neutropenia. Several
studies have shown that poor adherence to imatinib detrimentally affects responses and should be considered in
patients with a suboptimal response. The different dosing requirements of dasatinib (once daily with or without
food) and nilotinib (twice daily with fasting) may be an additional factor in selecting frontline agents. This review
compares and contrasts the three FDA approved first line TKI agents.
Introduction
Imatinib, which inhibits the tyrosine kinase activity of
BCR-ABL, was introduced as a first-line treatment for
chronic myeloid leukemia (CML) almost 10 years ago
and radically improved the outcome of patients with
CML. Imatinib has been the standard therapy for CML
due to its remarkable activity and mild toxicity. In the
IRIS study (International randomized study of interferon
vs STI571) of first-line treatment with imatinib or inter-
feron and cytarabine in patients with newly diagnosed
chronic phase (CP)-CML, patients in the imatinib arm
had an 8-year overall survival rate of 85% and freedom
from progression to advanced disease was 92% [1]. Ima-
tinib was also generally well tolerated during long-term
treatment.
Despite the responses observed with imatinib, a propor-
tion of patients develops resistance to imatinib or cannot
tolerate its side effects. This led to the development of
newer tyrosine kinase inhibitors (TKIs) of BCR-ABL,
including dasatinib, nilotinib, and bosutinib, that were
initially tested in clinical studies of patients with prior ima-
tinib therapy [2-5]. Dasatinib, nilotinib and bosutinib,
respectively, have 325-fold, 20-30-fold, and 30-fold
increased potency over imatinib against BCR-ABL kinase
in vitro [6-9]. Nilotinib has a similar chemical structure to
imatinib but has an improved topographical fit in the ABL
kinase pocket [6,7,9]. Dasatinib has a completely different
chemical structure to imatinib and, unlike imatinib and
nilotinib, binds BC R - A B Li nt h ea c t i v ec o n f o r m a t i o n
[10,11]. Bosutinib binds to an intermediate form of BCR-
ABL [8]. All three TKIs have activity against most of the
mutated forms of BCR-ABL kinase that have been asso-
ciated with clinical resistance to imatinib [6,9]. Dasatinib
100 mg once daily (QD) and nilotinib 400 mg twice daily
(BID) have been approved in the US and Europe as treat-
ments for patients with CML who are resistant or intoler-
ant to imatinib (dasatinib for all phases of CML, nilotinib
for CP and accelerated phase [AP]). Dasatinib 100 mg QD
and nilotinib 300 mg BID were recently approved in the
US for patients with newly diagnosed CP-CML. Bosutinib
is still undergoing clinical trials.
Clinical trials assessing the newer TKIs (dasatinib, nilo-
tinib, and bosutinib) as first-line therapies in newly diag-
nosed CP-CML are ongoing and results from trials of
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dasatinib, published clinical trials in newly diagnosed CP-
CML comprise: (i) DASISION (Dasatinib versus imatinib
study in treatment-naive CML patients), an international,
multicenter, randomized phase 3 trial of dasatinib
100 mg QD vs imatinib 400 mg QD (n = 519) [12]; and
(ii) a single-arm phase 2 trial of dasatinib 100 mg QD or
50 mg BID performed by M D Anderson Cancer Center
(MDACC), Houston, TX (n = 62) [13]. For nilotinib, pub-
lished clinical trials in newly diagnosed CP-CML com-
prise: (i) ENESTnd (Evaluating nilotinib efficacy and
safety in clinical trials - newly diagnosed patients), an
international, multicenter, randomized phase 3 trial of
nilotinib 300 mg BID vs nilotinib 400 mg BID vs imatinib
400 mg QD (n = 846) [14]; (ii) a single-arm phase 2 trial
of nilotinib 400 mg BID performed by MDACC (n = 61)
[15]; and (iii) a second single-arm phase 2 trial of niloti-
n i b4 0 0m gB I Dp e r f o r m e db yt h eI t a l i a nG I M E M A
(Gruppo Italiano malattie e matologiche dell’adulto)
group (n = 73) [4]. No data have been published from an
international, multicenter, randomized trial of bosutinib
vs imatinib (NCT00574873).
In this review, recent data for first-line treatment with
dasatinib or nilotinib will be discussed, with a specific
focus on safety and tolerability.
Efficacy of dasatinib and nilotinib compared with
imatinib in the first-line setting
In randomized trials, both dasatinib and nilotinib have
shown superior efficacy compared with imatinib as first-
line treatment for patients with CP-CML (Tables 1 and 2).
In the DASISION trial, responses were more frequent
with dasatinib vs imatinib treatment, including higher
12-month rates of complete cytogenetic response (CCyR;
83% vs 72%; P = 0.001) and major molecular response
(MMR; 46% vs 28%; P < 0.0001). Dasatinib also showed
superiority over imatinib in the primary trial endpoint,
the rate of confirmed CCyR (CCyR detected in two con-
secutive assessments), with 12-month rates of 77% vs
66%, respectively (P = 0.007). CCyR and MMR both
occurred faster with dasatinib compared with imatinib.
After a median 14 months of treatment, 1.9% of patients
h a dp r o g r e s s e dt oA P / b l a s tp h a s e( B P )w i t hd a s a t i n i b
compared with 3.5% with imatinib. No patient in whom a
MMR was achieved progressed to AP/BP [12]. In the
ENESTnd trial, the primary endpoint was the rate of
M M Ra t1 2m o n t h s ,a n db o t hn i l o t i n i ba r m s( 3 0 0m g
and 400 mg) had significantly higher rates compared
with the imatinib arm (43-44% vs 22%; P < 0.001). Rates
of CCyR achieved by 12 months were also significantly
higher for nilotinib vs imatinib (78-80% vs 65%; P <
0.001), and CCyR and MMR occurred faster in the niloti-
nib arms. After a median 14 months of treatment, fewer
nilotinib-treated patients had progressed to AP/BP phase
compared with imatinib-treated patients (< 1% vs 4%;
P ≤ 0.01 in an analysis of time to progression). Similar to
DASISION, no patient who had a MMR had progression
to AP/BP [14]. Five-year follow-up is planned in both
trials. Because available data suggest that both dasatinib
and nilotinib have broadly similar efficacy in terms of
their superiority over imatinib, it is likely that safety and
tolerability considerations for these agents will become
increasingly important when selecting first-line treatment
for CML.
The importance of adherence
Across various chronic diseases requiring long-term
treatment, poor adherence is associated with worse out-
comes [16]. Similarly, recent studies have shown that
Table 1 Rates of complete cytogenetic response (CCyR)
and major molecular response (MMR) to imatinib and
dasatinib in the DASISION trial
% of patients
Imatinib
400 mg QD
Dasatinib
100 mg QD
CCyR
3 months 31 54
6 months 59 73
9 months 67 78
12 months 72 83
MMR
3 months 0.4 8
6 months 8 27
9 months 18 39
12 months 28 46
Progression to AP/BP 3.5 1.9
AP: accelerated phase; BP: blast phase; QD: once daily.
Table 2 Rates of complete cytogenetic response (CCyR)
and major molecular response (MMR) to imatinib and
nilotinib in the ENESTnd trial
% of patients
Imatinib
400 mg QD
Nilotinib
300 mg BID
Nilotinib
400 mg BID
CCyR
6 months 45 67 63
12 months 65 80 78
MMR
3 months 1 9 5
6 months 12 33 30
9 months 18 43 38
12 months 22 44 43
Progression to AP/BP 4 < 1 < 1
AP: accelerated phase; BP: blast phase; QD: once daily.
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icantly lower response rates in patients with CP-CML.
In a prospective observational study (Adherence assess-
ment with Glivec: indicators and outcomes; ADAGIO),
adherence to imatinib treatment was analyzed in 169
patients with CML during a 90-day period and corre-
lated with overall responses to treatment. Only 14% of
patients were found to be perfectly adherent based on
pill counts (100% of imatinib taken), with 71% of
patients taking less imatinib than prescribed and 15%
taking more imatinib than prescribed. Importantly,
worse adherence was associated with worse treatment
responses; patients who had a suboptimal response to
imatinib had significant higher mean percentage of ima-
tinib not taken than those with an optimal response
(23% vs 7%; P = 0.005). Similarly, patients who failed to
achieve a CCyR on imatinib had a higher mean percen-
tage of pills not taken than patients who achieved a
CCyR (24% vs 9%; P = 0.012) [17]. In another prospec-
tive observational study performed at a single institu-
tion, 87 patients with CP-CML who had achieved a
CCyR on imatinib were monitored for adherence for 90
days using a microelectronic monitoring device. The
adherence rate was ≤ 90% in 26% and ≤ 80% in 14%.
There was a strong correlation between adherence to
imatinib and probabilities of MMR and CMR; patients
with ≤ 90% adherence had a lower 6-year rate of MMR
than patients with > 90% adherence (14% vs 94%; P =
0.002), no patient with ≤ 90% adherence achieved a
CMR, and no patient with ≤ 80% adherence achieved a
MMR. Significantly worse adherence rates were found
in patients with various adverse events (AEs), including
asthenia, nausea, muscle cramps, and bone or joint
pains, and also in patients who took imatinib indepen-
dently of meals. Patients who had their imatinib dose
increased had significantly worse adherence than
patients who remained on imatinib 400 mg QD (86% vs
99%; P = 0.021) [18]. In a retrospective analysis of imati-
nib treatment in clinical practice using US administra-
tive claims data, adherence to imatinib in 267 patients
was calculated using the medication possession rate
(MPR), ie, the total days supply of imatinib in a 1-year
period divided by 365. Overall, the mean MPR was 78%
and 31% of patients had a treatment interruption of at
least 30 consecutive days. Among the study population,
nonadherence was higher in patients with higher num-
bers of concomitant medications, women, patients with
more complex disease, and patients with a higher start-
ing dose of imatinib (≥ 600 mg/d). Although the reasons
for worse adherence in women were not examined, the
authors suggested that women may be more concerned
than men with AEs characteristic of imatinib treatment,
such as rash, edema, and weight gain [19].
The importance of adherence to imatinib in response
to treatment is further illustrated by the results of a
phase 3 randomized trial of imatinib 400 mg QD vs
800 mg/d (400 mg BID) in patients with newly diagnosed
CP-CML (Tyrosine kinase inhibitor optimization and
selectivity [TOPS]). Rates of MMR and CCyR at
12 months were similar between the two arms. However,
treatment responses in patients from the 800 mg/d arm
correlated with the dose of imatinib that could be toler-
ated, with higher MMR rates achieved in patients with an
average dose intensity of 600 mg/d or higher (62-63%)
compared with 400-599 mg/d (38%) or < 400 mg/d
(21%). In the 400 vs 800 mg arms, 18% vs 61% of patients
had a dose reduction, 52% vs 73% reported at least one
day with zero dose, 38% vs 67% had dose interruption
lasting longer than 5 days, and 16% vs 20% discontinued
treatment. The main reason for dose reduction in the
800 mg/d arm, but not the 400 mg/d arm, was AEs or
laboratory abnormalities. These data suggest that the
higher number of days off medication (ie, lower adher-
ence) in the high-dose imatinib arm counteracted any
positive effect of higher dosing [20].
Nonadherence is a possible cause for reduced
response to imatinib and should be considered in
patients with suboptimal response to imatinib [17]. The
AE profiles and tolerability of newer treatments are
therefore important considerations for clinical practice
in the first-line setting in terms of both efficacy and
safety.
Safety and tolerability of dasatinib and nilotinib
compared with imatinib in the first-line setting
Although dasatinib and nilotinib have been available for
use in therapy of CML in the second-line settings for
several years, new studies have provided the first direct
comparison with imatinib in the first-line setting. In
general, imatinib, dasatinib, and nilotinib are associated
with broadly similar types of AEs, although the relative
occurrence of different AEs varies between agents and
some AEs are specific to one drug (Tables 3 and 4). For
best management of CML patients receiving TKI ther-
apy, knowledge of potential toxicities, how to avoid
them, how to deal with them should they arise, and how
they may affect response and outcome, are important
factors. In general, BCR-ABL inhibitors are well toler-
ated and result in a limited number of higher-grade
toxicities (grades 3-4). Experience with imatinib in the
IRIS trial and with dasatinib and nilotinib in the sec-
ond-line setting suggest that AEs tend to occur early
during the course of treatment and late-onset toxicity is
uncommon [21-23]. Longer-term follow-up is needed to
confirm that the same is true for dasatinib and nilotinib
during first-line treatment. In general, most AEs
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managed with dose interruption and reduction and/or
supportive care.
Cytopenias
Cytopenias such as neutropenia, thrombocytopenia,
and anemia are the most common grade 3-4 AEs
observed in patients receiving imatinib, dasatinib, or
nilotinib. In the DASISION trial, grade 3-4 cytopenia
with dasatinib vs imatinib included similar rates of
neutropenia (20% vs 21%) and anemia (10% vs 7%),
whereas thrombocytopenia was more common with
dasatinib than with imatinib (19% vs 10%) [12]. Few
patients discontinued treatment due to cytopenia (1.5%
with dasatinib and 1.2% with imatinib) [12]. In the
MDACC study of dasatinib, grade 3-4 neutropenia,
thrombocytopenia, and anemia occurred in 21%, 10%,
and 6% of patients, respectively [13]. In the ENESTnd
trial, grade 3-4 neutropenia was less common in the
nilotinib 300 or 400 mg BID arms (12% and 10%,
respectively) compared with the imatinib arm (20%),
whereas grade 3-4 thrombocytopenia (10% vs 12% vs
9%) and anemia (3% vs 3% vs 5%) were similar
between treatment arms [14]. In the MDACC study of
nilotinib, grade 3-4 neutropenia, thrombocytopenia,
and anemia occurred in 12%, 11%, and 5% of patients,
respectively [15], whereas low rates (4%, 2%, and 0%)
were reported in the GIMEMA study [4].
Table 3 Drug-related nonhematologic adverse events,
that occurred in ≥ 10% of patients in any treatment arm,
hematologic adverse events, and biochemical
abnormalities, during the DASISION trial
All grade (grade 3-4), % of patients
Adverse event Imatinib
400 mg QD
Dasatinib
100 mg QD
Nonhematologic
Nausea 20 (0) 8 (0)
Diarrhea 17 (1) 17 (< 1)
Vomiting 10 (0) 5 (0)
Rash 17 (1) 11 (0)
Headache 10 (0) 12 (0)
Fatigue 10 (0) 8 (< 1)
Musculoskeletal pain 14 (< 1) 11 (0)
Muscle inflammation 17 (< 1) 4 (0)
Fluid retention 42 (1) 19 (1)
Superficial edema 36 (< 1) 9 (0)
Pleural effusion 0 (0) 10 (0)
Other 8 (< 1) 5 (1)
Hematologic
Neutropenia 58 (20) 65 (21)
Thrombocytopenia 62 (10) 70 (19)
Anemia 84 (7) 90 (10)
Biochemical abnormalities
Elevated AST NL (1) NL (< 1)
Elevated ALT NL (1) NL (< 1)
Elevated bilirubin NL (0) NL (1)
Elevated lipase NL (0) NL (0)
Hyperglycemia NL (0) NL (0)
Elevated amylase NL (0) NL (0)
Decreased phosphorus NL (21) NL (4)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; NL: not listed;
QD: once daily.
Table 4 Drug-related nonhematologic adverse events,
that occurred in ≥ 10% of patients in any treatment arm,
hematologic adverse events, and biochemical
abnormalities, during the ENESTnd trial
All grade (grade 3-4), % of patients
Adverse event Imatinib
400 mg
QD
Nilotinib
300 mg
BID
Nilotinib
400 mg
BID
Nonhematologic
Nausea 31 (0) 11 (< 1) 19 (1)
Diarrhea 21 (1) 8 (1) 6 (0)
Vomiting 14 (0) 5 (0) 9 (1)
Rash 11 (1) 31 (< 1) 36 (3)
Pruritus 5 (0) 15 (< 1) 13 (< 1)
Alopecia 4 (0) 8 (0) 13 (0)
Headache 8 (0) 14 (1) 21 (1)
Fatigue 8 (< 1) 11 (0) 9 (1)
Muscle spasm 24 (1) 7 (0) 6 (1)
Myalgia 10 (0) 10 (< 1) 10 (0)
Peripheral edema 14 (0) 5 (0) 5 (0)
Eyelid edema 13 (< 1) 1 (0) 2 (< 1)
Periorbital edema 12 (0) < 1 (0) 1 (0)
Hematologic
Neutropenia 68 (20) 43 (12) 38 (10)
Thrombocytopenia 56 (9) 48 (10) 49 (12)
Anemia 47 (5) 38 (3) 38 (3)
Biochemical abnormalities
Elevated AST 23 (1) 40 (1) 48 (3)
Elevated ALT 20 (2) 66 (4) 73 (9)
Elevated bilirubin 10 (< 1) 53 (4) 62 (8)
Elevated lipase 11 (3) 24 (6) 29 (6)
Hyperglycemia 20 (0) 36 (6) 41 (4)
Elevated creatinine 13 (< 1) 5 (0) 5 (0)
Elevated amylase 12 (1) 15 (< 1) 18 (1)
Elevated alkaline
phosphatase
33 (< 1) 21 (0) 27 (0)
Decreased phosphorus 45 (8) 32 (5) 34 (5)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; BID: twice
daily; QD: once daily.
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Rash was one of the most common nonhematologic AEs
[24,25]. In the IRIS study, rash occurred in 34%, although
grade 3-4 rash was infrequent (2%). Pruritus (7%) and
alopecia (4%) were also noted in smaller numbers of
patients [25]. In the DASISION trial, first-line dasatinib
treatment resulted in fewer cases of rash compared with
imatinib treatment (11% vs 17%), with grade 3-4 rash
occurring in 0% vs 1%, respectively. No rates were pro-
vided for pruritis or alopecia, suggesting that the frequen-
cies were < 10% in both arms [12]. In the MDACC study,
58% of patients experienced “skin toxicity” (grouped
term) with dasatinib, which was grade 3-4 in 2%. In addi-
tion, 8% experienced pruritus of which 2% was grade 3-4
[13]. Dermatologic toxicity seems to be more common
with nilotinib than imatinib. In the ENESTnd trial, rash
occurred in 31% taking nilotinib 300 mg BID, 36% taking
nilotinib 400 mg BID, and 11% taking imatinib (grade 3-4
in < 1% vs 3% vs 1%, respectively). Pruritus was also more
common in both nilotinib arms (15% with 300 mg BID
and 13% with 400 mg BID) compared with imatinib (5%),
as was alopecia (8% with nilotinib 300 mg BID, 13% with
nilotinib 400 mg BID, and 4% with imatinib) [14]. In sin-
gle-arm trials of first-line nilotinib 400 mg BID, rash
occurred in 49% (2% grade 3-4) of patients in the
MDACC trial [15] and in 42% (5% grade 3) in the
GIMEMA trial [4]. Pruritus also occurred in 21% of
patients in the GIMEMA trial (4% grade 3).
Gastrointestinal symptoms
Nausea, diarrhea, and vomiting are common in patients
receiving BCR-ABL inhibitor therapy, although recent
data indicate that gastrointestinal (GI) disturbances
occur less often in patients receiving dasatinib or niloti-
nib compared with those receiving imatinib. In the
DASISION trial, nausea (8% v 20%) and vomiting (5%
vs 10%) both occurred less frequently with dasatinib
compared with imatinib, whereas rates of diarrhea were
similar (17% in both arms). Grade 3-4 diarrhea was
reported in < 1-1%, and no patients in either arm
experienced grade 3-4 nausea or vomiting [12]. In the
MDACC trial of dasatinib, higher rates of GI AEs were
reported, including diarrhea in 53% (2% grade 3-4), nau-
sea in 45% (0% grade 3-4), and vomiting in 21% (0%
grade 3-4) [13]. In the ENESTnd trial, rates of GI AEs
were lower with nilotinib 300 mg and 400 mg vs imati-
nib, including nausea (11% vs 19% vs 31%), diarrhea (8%
vs 6% vs 21%), and vomiting (5% vs 9% vs 14%), of
which 0-1% were grade 3-4 cases in all arms [14]. In the
MDACC study of first-line nilotinib, nausea and diar-
rhea were reported in 38% and 21% of patients, respec-
tively, (no grade 3-4), and diarrhea occurred in 7% (2%
grade 3-4) [15]. In the GIMEMA study, 11% of patients
experienced nausea/vomiting (1% grade 3-4) and 7% had
diarrhea (2% grade 3) [4].
Edema
Fluid retention is common with imatinib, as shown by
56% of patients receiving imatinib in the IRIS trial
experiencing superficial edema and 13% having weight
gain [25]. First-line dasatinib and nilotinib treatment are
associated with lower rates of edema. In the DASISION,
superficial edema (grouped term) was much less fre-
quent with dasatinib (9%) compared with imatinib
(36%), and rates of grade 3-4 superficial edema were low
(0% vs < 1%, respectively) [12]. In the MDACC study of
dasatinib, edema was reported in 32% of patients (no
grade 3-4) [13]. In the ENESTnd trial, different types of
edema were reported separately. In the nilotinib 300 mg
BID, nilotinib 400 mg BID, and imatinib arms, periph-
eral edema occurred in 5% vs 5% vs 14%, eyelid edema
occurred in 1% vs 2% vs 13%, and periorbital edema
occurred in < 1% vs 1% vs 12% [14]. In the GIMEMA
trial, peripheral edema was reported in 4% of patients
receiving nilotinib and all cases were grade 1-2 [4]. Data
for edema were not reported in the MDACC study of
nilotinib [15].
Pleural effusion
Pleural effusion is rare with nilotinib and imatinib but is
a more prominent side effect of dasatinib treatment
[26,27]. In the DASISION trial, 10% of patients in the
dasatinib arm had a pleural effusion whereas no patient
receiving imatinib reported this AE. Dasatinib-associated
pleural effusion was grade 1 in 2% and grade 2 in 8% of
patients, with no pleural effusion grade 3 or above. The
occurrence of pleural effusion did not affect the efficacy
of dasatinib, as shown by CCyR being achieved in 24/26
patients (92%) who had a pleural effusion. In the DASI-
SION trial, pleural effusion was managed using dose
adjustments and/or medical intervention, including dose
interruption in 19 patients, diuretics in 12 patients, dose
reduction in eight patients, corticosteroids in seven
patients, and therapeutic thoracentesis in one patient.
Discontinuation due to pleural effusion occurred in
three patients (1% of the dasatinib arm) [12]. In the
MDACC study of first-line dasatinib, the rate of pleural
effusion (13%) was similar to DASISION, and one case
of grade 3/4 pleural effusion was reported. Pleural effu-
sion occurred less frequently in patients who received
dasatinib 100 mg QD (6%) compared with 50 mg BID
(19%), and two patients (3%) discontinued treatment
due to pleural effusion [13]. In the ENESTnd study,
pleural effusion occurred in a small number (< 1%) of
nilotinib-treated patients [28] and was not reported in
the single-arm studies of nilotinib.
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In 2006, a report was published describing ten indivi-
duals who developed severe congestive heart failure
(CHF) on imatinib treatment. Based on laboratory stu-
dies, the authors suggested that this effect could occur
as a result of inhibition of physiologic ABL activity in
cardiac tissue [29]. Subsequent retrospective analyses
estimated that the frequency of CHF or left ventricular
dysfunction during imatinib therapy for CML was
0.5-1.1% [30-32].
In TKI studies, instances of QT prolongation were
reported [33-37]. In particular, in studies of nilotinib in
patients with imatinib resistance or intolerance, sudden
death was reported in 0.6% of patients, with a similar
rate of occurrence in an expanded-access program. The
timing of sudden death relative to initiation of nilotinib
suggested that ventricular repolarization abnormalities
may have contributed to their occurrence [34]. In recent
TKI trials, patients with significant cardiac disease were
excluded from participating.
In randomized trials of nilotinib or dasatinib vs imati-
nib, close monitoring for QT prolongation and changes
in left ventricular ejection fraction was performed. Dur-
ing nilotinib or imatinib treatment in the ENESTnd
study, no patient had a QTc interval of > 500 msec and
no decrease from the baseline in the mean left ventricu-
lar ejection fraction was observed at any time. Eleven
patients across all three study arms had an ischemic
heart disease event, although no further details were
provided regarding relative frequency between arms
[14]. In the MDACC study of front-line nilotinib, there
were two instances of hypertension and one instance of
QTc prolongation (all classed as grade 1-2) [15]. In the
GIMEMA study of nilotinib, 584 electrocardiograms
from 73 patients were reviewed. In addition to transi-
ent/irreverent abnormalities noted in 22% of patients,
QTc interval prolongation to > 450 msec was noted in 2
cases [4]. In the DASISON trial, 2% vs 4% of dasatinib
and imatinib arms had QTc intervals between 450-500
msec, and one patient (0.4%) in each group had a QTc
interval of > 500 msec. Median changes in QTc interval
from baseline were 3 msec in the dasatinib group and 8
msec in the imatinib group [12].
Bleeding
Bleeding was noted in studies of dasatinib in the sec-
ond-line setting, mostly in patients with severe throm-
bocytopenia and more commonly in patients with
advanced disease [38]. In vitro data suggest that dasati-
nib reversibly inhibits platelet activation [39]. In the
DASISION trial, GI bleeding or other bleeding events
occurred at a similar frequency in both treatment arms
(5%). One patient in the dasatinib group and two
patients in the imatinib group reported a grade 3-4
bleeding event [12].
Other nonhematologic AEs
Mild to moderate nonhematologic AEs such as head-
ache, fatigue, muscle pains/cramps, and joint pain are
commonly seen with BCR-ABL inhibitor treatment.
These effects are usually easily managed without dose
reduction and rarely cause dose interruptions. Recent
data suggest that some of these AEs occur at different
rates with dasatinib or nilotinib compared with imatinib.
In the DASISION study, musculoskeletal AEs were less
common with dasatinib compared with the imatinib
arm, including myalgia (6% vs 12%), muscle inflamma-
tion (4% vs 17%), and musculoskeletal pain (11% v 14%).
Rates of fatigue (8% v 10%) and headache (12% vs 10%)
were similar in both arms. With each of these AEs,
≤ 1% of patients had a grade 3-4 event [12]. In the
MDACC study of dasatinib, pain in joint/muscle (com-
bined grouping; 74%), fatigue (73%), and headache (56%)
were reported at high rates (grade 3-4 in 6%, 6%, and
2%, respectively) [13]. In the ENESTnd trial, muscle
spasm occurred at a lower frequency in the nilotinib
arms (6-7%) compared with the imatinib arm (24%).
Myalgia occurred at a similar rate across all three arms
(10%), as did fatigue (8-11%). However, headache
occurred at a higher frequency in the nilotinib 300 mg
BID (14%) and 400 mg BID (21%) treatment groups
than in the imatinib treatment group (8%). Rates of
grade 3-4 events with these AEs were ≤ 1% [14]. Similar
to the MDACC study of dasatinib, the study of nilotinib
at the same institution reported substantially higher
rates of fatigue (67%; grade 3-4 in 3%) and headache
(39%; no grade 3-4) than in the randomized study. Mus-
culoskeletal AEs were reported as separate categories;
10% of patients experienced muscle cramp (0% grade 3-
4) and 10% experienced joint pain (3% grade 3-4) [15].
In the GIMEMA study, 41% of patients taking nilotinib
experienced bone/muscle/joint pain (combined group-
ing), of which 4% were grade 3. In addition, 30% experi-
enced headache and 22% experienced fatigue (no grade
3-4 in each case) [4].
Biochemical abnormalities
Rates of biochemical abnormalities vary in patients
receiving different BCR-ABL inhibitors and seem to be
most common during nilotinib treatment. In the DASI-
SION trial, grade 3-4 hypophosphatemia occurred in 4%
of patients treated with dasatinib compared with 21% of
the patients treated with imatinib. Rates of other grade
3-4 biochemical abnormalities were low in both treat-
ment arms, including markers of hepatic toxicity (ele-
vated alanine aminotransferase [ALT] or aspartate
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bilirubin 1% vs 0%) and pancreatic toxicity (no grade
3/4 elevations in lipase or amylase, or cases of hypergly-
cemia were recorded). Rates of all-grade biochemical
abnormalities were not reported [40]. Four imatinib-
treated patients but no dasatinib-treated patients discon-
tinued therapy because of biochemical abnormalities
[12]. In the MDACC study of dasatinib, hypophosphate-
mia occurred in 6% (2% grade 3-4) of patients, hypergly-
cemia occurred in 24% (2% grade 3-4), and elevated
ALT or AST occurred in 16% and 15%, respectively (no
grade 3-4 cases) [13].
In the ENESTnd trial, more nilotinib-treated patients
than imatinib-treated patients had biochemical abnorm-
alities associated with liver and pancreatic toxicity. With
nilotinib 300 mg BID or 400 mg BID or imatinib, ALT
was elevated in 66% vs 73% vs 20% of patients, respec-
tively (grade 3-4 in 4% vs 9% vs 2%), AST was elevated
in 40% vs 48% vs 23% (grade 3-4 in 1% vs 3% vs 1%),
and bilirubin was elevated in 53% vs 62% vs 10%, (grade
3-4 in 4% vs 8% vs < 1%). Elevated lipase was observed
in 24-29% of patients receiving nilotinib (6% grade 3-4)
compared with 11% of patients receiving imatinib (3%
grade 3-4). Respective rates of hyperglycemia were
36-41% (4-6% grade 3-4) vs 20% (no grade 3-4) and ele-
vated amylase occurred in 15-18% vs 12% (grade 3-4 in
< 1-1%) of patients. Hypophosphatemia occurred in
32-34% of nilotinib arms (5% grade 3-4) and 45% of the
imatinib arm (8% grade 3-4). All newly occurring grade
3-4 biochemical abnormalities occurred within the first
2 months of therapy. Discontinuations due to biochem-
ical abnormalities occurred in 2% of both nilotinib arms
and 1% of the imatinib arm [14]. In other studies of
nilotinib as front-line therapy, ALT elevation occurred
in 42-48% (0-8% grade 3) of patients, AST elevation
occurred in 29-46% (0-3% grade 3), and bilirubin eleva-
tion occurred in 39-53% (grade 3-4 in 7-16%) [4,15].
Elevated markers of pancreatic toxicity were reported in
both studies. However, hyperglycemia was more com-
mon in the MDACC study (44%, grade 3-4 in 5%) than
elevated lipase (10%, grade 3/4 in 5%) or amylase (3%,
grade 3/4 in 2%), whereas hyperglycemia (12%, grade 3
in 3%) was less common in the GIMEMA study than
elevated lipase (29%, grade 3-4 in 8%) or amylase (18%,
grade 3 in 4%) [4,15]. One patient in the GIMEMA
study discontinued treatment following lipase elevation.
Bilirubin elevation on nilotinib may be due in part to
nilotinib inhibition of UGT1A1 activity. UGT1A1 cata-
lyzes the conjugation of hepatic bilirubin and poly-
morphisms in the promoter region of UGT1A1 are
associated with Gilbert’s Syndrome (inherited mild,
chronic, unconjugated hyperbilirubinemia in the absence
of liver disease or overt hemolysis). Reduced UGT1A1
expression due to polymorphisms is associated with
elevation of bilirubin in plasma [41,42]. UGT1A1 pro-
moter polymorphism has been found to increase the
risk of nilotinib-induced bilirubin elevation [43].
Dose adjustments and discontinuations due to
toxicity
The rate of discontinuations because of drug toxicity pro-
vides a measure of the frequency of the most problematic
AEs. In the DASISION trial, discontinuations following
study drug toxicity occurred in 5.0% of the dasatinib arm
and 4.3% of the imatinib arm. Of these, hematologic toxi-
city led to discontinuation in 1.6% vs 1.2%, and nonhema-
tologic toxicity led to discontinuation in 3.5% vs 3.1%,
respectively. Median doses of drug delivered were 99 mg/d
in the dasatinib 100 mg QD arm vs 400 mg/d in the imati-
nib 400 mg QD arm. Data for dose interruptions and
reductions have not been reported [12]. In the ENESTnd
trial, discontinuations due to AEs occurred in 5% with
nilotinib 300 mg BID, 9% with nilotinib 400 mg BID, and
7% with imatinib. Median doses of drug delivered were
592 mg/d in the nilotinib 300 mg BID arm, 779 mg/d in
the nilotinib 400 mg BID arm, and 400 mg in the imatinib
400 mg QD arm. Respective rates of dose reduction/inter-
ruption were 59%, 66%, and 52%. Median cumulative
durations of interruptions due to AEs or biochemical
abnormalities were 19 days, 22 days, and 15 days, respec-
tively [14].
Future directions with BCR-ABL inhibitors
Bosutinib
Data are awaited from the randomized phase 3 trial of
bosutinib vs imatinib for first-line treatment for newly
diagnosed CML [37]. However, data have been reported
for the efficacy and safety of bosutinib in patients with
CP-CML who had prior imatinib treatment. Response
rates with bosutinib were comparable to those seen in
trials of dasatinib and nilotinib in the second-line setting,
including CCyR in 50% and MMR in 52% of evaluated
patients, of which 32% were complete. At 24 months,
rates of progression-free and overall survival were 80%
and 95%, respectively. Responses were similar in patients
with or without BCR-ABL mutations. Safety data indicate
that bosutinib has a distinct safety profile compared with
currently approved BCR-ABL inhibitors. AE rates should
be interpreted with caution based on previous observa-
tions with dasatinib and nilotinib that AEs generally
occur more frequently with second-line (post-imatinib)
treatment compared with first-line treatment. Grade 3-4
thrombocytopenia, neutropenia, and anemia occurred in
24%, 16%, and 12%, respectively of patients receiving
bosutinib. GI AEs were common with bosutinib treat-
ment, including diarrhea in 84% of patients (9% grade
3-4), nausea in 44% (2% grade 3-4), and vomiting in 36%
(3% grade 3-4). In addition, 34% of patients suffered from
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3-4), 21% had fatigue (1% grade 3-4), 14% had headache
(no grade 3-4), and 13% had joint pain (< 1% grade 3-4).
Rates of fluid retention AEs were not reported, indicating
a frequency of < 10%. Of grade 3-4 biochemical abnorm-
alities, elevated ALT occurred in 10% of patients, elevated
AST in 5%, elevated lipase in 7%, elevated glucose in 3%,
decreased phosphate in 8%, and hypermagnesemia in
12%. In addition, 19% of patients receiving bosutinib in
this study discontinued treatment due to AEs and 45%
had a dose reduction due to AEs. The median dose of
bosutinib was 454 mg/d (starting dose was 500 mg/d)
[44]. Overall, preliminary data from this phase 1/2 trial
indicate that bosutinib is an active agent for patients with
CP-CML who have failed on prior imatinib treatment,
with activity against a range of BCR-ABL mutations, and
an acceptable toxicity profile.
Inhibitors for T315I mutant
Resistance to imatinib or relapse in patients with CML
arises most frequently because of point mutations within
the BCR-ABL coding sequence [45-48]. In vitro data has
shown that dasatinib, nilotinib, and bosutinib effectively
inhibit the majority of mutated forms of BCR-ABL that
have been associated with imatinib resistance in the
clinic [6,9,49]. However, the T315I point mutation con-
fers resistance to imatinib, dasatinib, nilotinib, and bosu-
tinib [50,51]. Although data are not yet available to
indicate how frequently T315I will cause resistance to
the newer agents, this mutation represents an “Achilles’
heel” for CML therapy.
Several TKIs that are active against the T315I-mutated
form of BCR-ABL are being developed. MK-0457, a potent
inhibitor of BCR-ABL and aurora kinases, was the first
agent to show clinical activity against the T315I mutation;
however, development of this drug was halted due to car-
diac toxicity [52]. Other BCR-ABL/aurora kinases inhibi-
tors with activity against T315I are in clinical
development, including XL228, PHA-739358 (danusertib),
and AT9283 [53-57]. Ponatinib (AP24534) is a multitar-
geted BCR-ABL/SRC kinase inhibitor with potent in vitro
activity against all tested mutants of BCR-ABL including
T315I, and clinical activity has been reported in patients
with a T315I mutation [58-60]. Further clinical studies of
ponatinib are ongoing, most notably a single-arm phase 2
study in patients with CML or Ph+ acute lymphoblastic
leukemia (ALL) who either are resistant or intolerant to
either dasatinib or nilotinib, or who harbor the T315I
mutation (Ponatinib Ph+ ALL and CML evaluation
[PACE]; NCT01207440). Switch pocket kinase inhibitors,
such as DCC-2036 and DCC-2157, target the sites
involved in controlling the conformation of BCR-ABL,
which ultimately controls the activity state of the kinase.
These agents are active against cells expressing a variety of
BCR-ABL mutations, including T135I. A phase 1 study of
DCC-2036 in patients with T315I or failure on two differ-
ent TKIs is underway (NCT00827138) [61,62]. Omacetax-
ine (previously homoharringtonine) is a naturally
occurring alkaloid derived from evergreen trees that
induces apoptosis in leukemic cells, including those har-
bouring the T315I mutation [63-65]. In a phase 2/3 trial in
patients with CML and a T315I mutation, omacetaxine
treatment in the subset of patients with CP-CML resulted
in a CCyR in 10% and a MMR in 15% [66]. The underlying
mechanism for omacetaxine inhibitory effects on leukemic
cells is still unknown. Studies of omacetaxine in patients
with CML, either alone or in combination with other
treatments, are ongoing.
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